Vaxil Bio Ltd

Research Vaxil Bio Ltd (VXL) on Bullrun: valuation model: 630.5% undervalued, market cap CAD 717.12K, P/E 1.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVXL
• ExchangeV
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCAD
• Valuation signal630.5% undervalued
• Market capCAD 717.12K
• P/E1.0
• Financial periodQ3 2025
• Net income-CAD 20.00K
• Free cash flow-CAD 28.00K

Valuation Snapshot

Bullrun's latest valuation model marks Vaxil Bio Ltd as 630.5% undervalued; latest market cap is CAD 717.12K; P/E is 1.0.

About Vaxil Bio Ltd

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company is headquartered in Toronto, Canada.

Frequently asked questions

Is Vaxil Bio Ltd overvalued or undervalued?

Bullrun's valuation model currently marks Vaxil Bio Ltd as 630.5% undervalued.

What is Vaxil Bio Ltd's market cap?

Vaxil Bio Ltd's market capitalization is CAD 717.12K.

What is Vaxil Bio Ltd's P/E ratio?

Vaxil Bio Ltd's price-to-earnings (P/E) ratio is 1.0.

What does Vaxil Bio Ltd do?

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company is headquartered in Toronto, Canada.